PAREXEL International Reaches New 1-Year High on Analyst Upgrade (PRXL)
PAREXEL International (NASDAQ:PRXL) hit a new 52-week high on Monday after Sterne Agee raised their price target on the stock from $36.00 to $42.00, AnalystRatingsNetwork reports. The stock traded as high as $57.59 and last traded at $57.00, with a volume of 397,987 shares. The stock had previously closed at $56.20.
A number of other analysts have also recently weighed in on PRXL. Analysts at Robert W. Baird raised their price target on shares of PAREXEL International from $64.00 to $66.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of PAREXEL International from $58.00 to $59.00 in a research note on Thursday. They now have a “hold” rating on the stock. Finally, analysts at KeyCorp initiated coverage on shares of PAREXEL International in a research note on Wednesday, July 2nd. They set a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $56.63.
The stock has a 50-day moving average of $53.98 and a 200-day moving average of $51.74. The company has a market cap of $3.238 billion and a price-to-earnings ratio of 24.98.
PAREXEL International (NASDAQ:PRXL) last announced its earnings results on Thursday, August 7th. The company reported $0.65 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.62 by $0.03. The company had revenue of $510.60 million for the quarter, compared to the consensus estimate of $508.99 million. During the same quarter last year, the company posted $0.50 earnings per share. PAREXEL International’s revenue was up 10.3% compared to the same quarter last year. Analysts expect that PAREXEL International will post $2.70 EPS for the current fiscal year.
PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.